Healthcare / Medical DevicesNasdaqGS
$9.96
-0.27 (-2.69%)
FCF base 3Y
$5.08
-20.1% CAGR · yield 9.2%
FCF base 5Y
$4.94
-13.1% base · -4.0% expected
Precio de entrada
$2.05
MOS 27% · confianza 49%
FCF escenarios
modelled · normalized FCF $20.4M · quality 40.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
5/9
balance/quality
Valuation
100/100
+286.5% upside
5Y CAGR
-4.0%
34/100
Data QA
100/100
SEC 100%
Sin guardar todavía.
Market Cap
$420M
P/E
N/A
•EV/EBITDA
947.2x
↑ROE
-14.9%
↓Gross Margin
34.4%
↓Debt/Equity
0.78
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2015–2025 · 10 años de histórico normalizado
Revenue CAGR
+2.9%
FCF CAGR
-9.5%
FCF margin
2.2%
FCF / Net income
-0.27x
Latest source
SEC-backed
Margin decomposition
Último año: revenue $844.6M · net income $-70.3M · FCF $18.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025SEC | 2024SEC | 2023SEC | 2022SEC | 2021SEC | 2020SEC | 2019SEC | 2018SEC | 2017SEC | 2016SEC | 2015SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||
| Revenue | $844.6M | $844.6M | $811.0M | $893.4M | $859.4M | $818.1M | $738.3M | $780.6M | $773.4M | $698.1M | $620.1M | $632.3M |
| Net Income | $-70.3M | $-70.3M | $-48.8M | $47.4M | $30.3M | $17.4M | $-57.9M | $15.5M | $27.5M | $51.6M | $68.5M | $80.0M |
| EBITDA | $700000.00 | $700000.00 | $62.9M | $91.2M | $114.5M | — | — | — | — | — | — | — |
| EPS | -1.70 | -1.70 | -1.20 | 1.07 | 0.73 | 0.43 | -1.49 | 0.40 | 0.72 | 1.36 | 1.82 | 2.12 |
| Gross Margin | 34.4% | 34.4% | 31.7% | 32.5% | 33.0% | 33.2% | 25.8% | 32.9% | 32.8% | 36.3% | 40.1% | 39.6% |
| Operating Margin | -3.3% | -3.3% | 4.0% | 8.6% | 10.3% | 9.1% | -4.6% | 5.9% | 5.8% | 12.0% | 17.6% | 20.2% |
| Net Margin | -8.3% | -8.3% | -6.0% | 5.3% | 3.5% | 2.1% | -7.8% | 2.0% | 3.6% | 7.4% | 11.0% | 12.7% |
| Balance Sheet | ||||||||||||
| Debt/Equity | 0.78 | 0.78 | 0.84 | 0.78 | 0.78 | 0.90 | 1.01 | 0.89 | 0.91 | 1.28 | 0.00 | — |
| Current Ratio | 3.20 | 3.20 | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||
| Free Cash Flow | $18.8M | $18.8M | $20.4M | $87.7M | $-4.4M | $77.5M | $-10.3M | $52.1M | $64.9M | $55.0M | $45.3M | $50.9M |
| Returns | ||||||||||||
| ROE | -14.9% | -14.9% | -9.2% | 8.3% | 5.7% | 3.6% | -12.8% | 3.5% | 6.5% | 13.6% | 13.0% | 16.1% |
| Valuation | ||||||||||||
| P/E | — | — | — | 9.41 | 13.79 | 23.42 | — | 25.18 | 13.99 | 7.40 | 5.53 | 4.75 |
| EV/EBITDA | 947.20 | 947.20 | 12.29 | 13.94 | 10.76 | — | — | — | — | — | — | — |
| P/B | 0.88 | 0.88 | 0.78 | 0.89 | 0.79 | 0.84 | 0.86 | 0.87 | 0.91 | 1.01 | 0.72 | 0.77 |
| Growth & Yield | ||||||||||||
| Revenue Growth | 4.1% | 4.1% | -9.2% | 4.0% | 5.0% | 10.8% | -5.4% | 0.9% | 10.8% | 12.6% | -1.9% | — |
| EPS Growth | -41.7% | -41.7% | -212.1% | 46.6% | 69.8% | 128.9% | -472.5% | -44.4% | -47.1% | -25.3% | -14.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+29.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.20 → -1.70
Residual
+29.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.